Journal article
Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
Authors
Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz MC; Berry WR; Mukherjee S; Winquist E
Journal
Journal of Clinical Oncology, Vol. 32, No. 15_suppl, pp. 5051–5051
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.5051
ISSN
0732-183X